Analysis on Mycoplasma pneumonia 23SrRNA gene mutation site and drug resistance phenotype

doi:10.3969/j.issn.1673-8640.2013.01.003

Abstract

Abstract: Objective　To investigate the infection situation of Mycoplasma pneumonia（Mp）in patients with community-acquired respiratory tract infection and the molecular drug resistance mechanisms of macrolide，and to analyze the relationship between 23SrRNA gene mutation site of isolates resistant to Mp and drug resistance phenotype. Methods　A total of 400 throat swab specimens of community-acquired respiratory tract infection were cultured to isolate Mp，the clinical isolates were identified by nested polymerase chain reaction，and the in vitro antibiotic sensitivity test was performed for identifying macrolide-resistant isolates through the minimal inhibitory concentration(MIC)．The sequences of macrolide-resistant 23SrRNA gene were detected. The sequences were compared to the corresponding sequences of M129． The relationship between mutation site and drug resistance phenotype was analyzed. Results　A total of 50 Mp were isolated from 400 throat swab specimens．Of the 50 isolates，32 isolates were susceptible to macrolide，and 18 isolates were resistant to macrolide．The 18 clinical isolates appeared mutation A2063G，A2064G and A2067G，separately. A2063G showed 14 ring macrolide resistance．A2064G showed 14 and 16 ring macrolide resistances. A2067G showed josamycin resistance. Conclusions　Mp to macrolide resistance is serious，and the mutation of 23SrRNA gene is a predominant mechanism that contributes to the macrolide resistance. Through the analysis of 23SrRNA gene mutation site and drug resistance phenotype，the clinical Mp drug resistance situation is obtained. The theoretical guidance for reasonable selection and application of antibiotics is provided.

Key words: Mycoplasma pneumonia, Gene mutation, Macrolide, Microbial sensitivity test

YE Yun，LI Suliang，JIANG Ping，WANG Yao，YANG Chao. Analysis on Mycoplasma pneumonia 23SrRNA gene mutation site and drug resistance phenotype[J]. , 2013, 28(1): 11-16.

References

[1]Schmidt-Ioanas M，Bender M，Roth A，et al. Serologic early diagnosis of pneumonia caused by Mycoplasma pneumoniae[J]. Dtsch Med Wochenschr，2006，131(12):613-617.
[2]Harris JA，Kolokathis A，Campbell M，et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children[J]. Pediatr Infect Dis J，1998，17(10):865-871.
[3]Bébéar CM，Pereyre S．Mechanisms of drug resistance in Mycoplasma pneumoniae[J].Curr Drug Targets Infect Discord，2005，5(3):263-271.
[4]Pereyre S，Charron A，Renaudin H，et al．First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years[J].J Clin Microbiol，2007，45(11):3534-3539.
[5]Matsuoka M，Narita M，Okazaki N，et al. Characteri-zation and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan[J]．Antimicrob Agents Chemother，2004，48(12)：4624-4630.
[6]Pereyre S，Guyot C，Renaudin H，et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae[J]. Antimicrob Agents Chemother，2004，48(2):460-465.
[7]Takahata M，Shimakura M，Hori R ，et al. In vitro and in vivo efficacies of T-3811ME（BMS-284756）against Mycoplasma pneumoniae[J]. Antimicrob Agents Chemother，2001，45(1):312-315.
[8]Xu YC，Zhu LJ，Xu D，et al.Epidemiological characte-ristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou[J]. World J Pediatr，2011，7(3):240-244. 
[9]Youn YS，Lee KY，Hwang JY，et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia[J]. BMC Pediatr，2010，10:48.
[10]郭丽，张善辉，王平平.儿童血清肺炎支原体感染情况调查[J].检验医学，2012，27(11)：959-960.
[11]Wilson DN，Harms JM，Nierhaus KH，et al. Species-specific antibiotic-ribosome interactions：implications for drug development[J].Biol Chem，2005，386(12):1239-1252.
[12]Zaman S，Fitzpatrick M，Lindahl L.Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli[J]. Mol Microbiol，2007，66(4):1039-1050.
[13]Morozumi M，Iwata S，Hasegawa K，et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia[J]. Antimicrob Agents Chemother，2008，52(1):348-350. 
[14]辛德莉，糜祖煌，侯安存，等．肺炎支原体对红霉素耐药机制研究[J]．实用儿科临床杂志，2005，20(7)：666-667．
[15]Averbuch D，Hidalgo-Grass C，Moses AE，et al． Macrolide resistance in Mycoplasma pneumoniae，Israel，2010[J]. Emerg Infect Dis，2011，17(6):1079-1082.
[16]姜毅，李温慈，徐海滨，等. 小儿肺炎咽拭子肺炎支原体培养及药敏分析[J]. 中华医院感染学杂志，2011，21(9):1925-1927.